Abstract
Resolution of the three-dimensional structures of several Hepatitis C virus (HCV) proteins, together with the development of replicative cell culture systems, has led to the identification of a number of potential targets for direct-acting antiviral agents (DAA). Numerous families of drugs that potently inhibit the HCV life cycle in vitro have been identified, and some of these molecules have reached early to late clinical development. Two NS3-4A protease inhibitors, telaprevir and boceprevir, were approved in Europe and the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1. A number of other DAAs are at the clinical developmental stage in combination with pegylated IFN-α and ribavirin or with other DAAs in IFN-free regimens, with or without ribavirin. They include second-wave, first-generation, and second-generation NS3-4A protease inhibitors, nucleoside/nucleotide analogue inhibitors, and non-nucleoside inhibitors of HCV RNA-dependent RNA polymerase, inhibitors of nonstructural protein 5A and host-targeted agents, such as cyclophilin A inhibitors and microRNA-122 antagonists. The proof of concept that IFN-free regimens can lead to HCV eradication has recently been brought. This chapter provides an overview of the current treatment of HCV infection and discusses the future of HCV therapy with new anti-HCV drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F et al (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207–1217
Brainard DM, Perty A, van Dyck K, Nachbar RB, de Lepeleire I, Caro L, Stone JA et al (2010) Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52:706A–707A
Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourliere M et al (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131:1040–1048
Brown NA, Vig P, Ruby E, Muchnik A, Pottorf E, Knox SJ, Febbraro S et al (2010) Safety and pharmacokinetics of PPI-461, a potent new hepatitis C virus NS5A inhibitor with pan-genotype activity. Hepatology 52:S464
Chayama K, Takahashi S, Kawakami Y, Ikeda K, Suzuki F, Toyota J, Karino Y et al (2011) Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders. Hepatology 54:1428A
Chevaliez S, Rodriguez C, Soulier A, Ahmed-Belkacem A, Hézode C, Pawlotsky JM (2011) Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol 54(1):S30
Chevaliez S, Rodriguez C, Pawlotsky JM (2012) New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303–1313
Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B et al (2012) Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 142:790–795
Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J (2008) Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 53:967–976
Coelmont L, Gallay P, Bobardt M, Kaptein S, Paeshuyse J, Vliegen I, Vuagniaux G et al (2009) Particular in vitro anti-HCV activities and resistance profile of the cyclophylin inhibitor DEBIO-025. J Hepatol 50(1):S36
Dahari H, Guedj J, Perelson AS, Layden TJ (2011) Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep 10:214–227
de Bruijne J, de Rooij JV, van Vliet A, Leempoels J, Zhou XJ, Weegink C, Molenkamp R et al (2010) Phase I study in healthy volunteers and patients with IDX-375, a novel non-nucleoside HCV polymerase inhibitor. Hepatology 52:1219A
Detishin V, Haazen W, Robison H, Robarge L, Olek E (2010) Virological response, safety and pharmacokinetic profile following single- and multiple-dose administration of ACH-0141625 protease inhibitor to healthy volunteers and HCV genotype 1 patients. J Hepatol 52(1):S468
Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL et al (2009) Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antiviral Ther 14:23–32
European Association for the Study of the Liver (2011) EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 55:245–264
Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P et al (2011) Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 54:1130–1136
Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M (2011) Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 85:7312–7320
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D et al (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467–1475
Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, Berrey MM (2011) Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 54(1):377A
Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes RG, Berrey MM (2012) ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. J Hepatol 56(2):S438
Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96–100
Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335–1374
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases. Hepatology 54:1433–1444
Goldwater R, DeMicco M, Zong JA, Chittik GE, Yuen GJ, West S, Kagel J et al (2010) Safety, pharmacokinetics and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS-9256. Hepatology 52:717A–718A
Guedj J, Perelson AS (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53:1801–1808
Herrmann E, Lee HJ, Marinos G, Modi M, Zeuzem S (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37:1351–1358
Hotho D, deBruijne J, O’Farrell A, Boyea T, Li J, Weegink CJ, Schinkel J et al (2009) Accelerated clinical trial design to assess the safety, tolerability and antiviral activity of PHX1766, a novel HCV NS3/4A protease inhibitor in healthy volunteers and chronic hepatitis C patients. Hepatology 50:1031A–1032A
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416
Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD et al (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631–639
Larrey D, Benhamou Y, Lohse AW, Trepo C, Moelleken C, Bronowicki JP, Arasteh K et al (2009) Safety, pharmacokinetics and antiviral effect of BI207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 50(1):S383–S384
Lawitz E, Sulkowski M, Jacobson I, Faruqui S, Kraft WK, Maliakkal B, Allbrahim M et al (2008) Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection. Hepatology 48:403A
Lawitz E, Rodriguez-Torres M, DeMicco M, Nguyen T, Godofsky E, Appleman J, Rahimy M et al (2009) Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 50(1):S384
Lawitz E, Gaultier I, Poordad F, De Jesus E, Kowdley K, Sepulveda G, Cohen D et al (2010) Four week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450r) in combination with pegylated interferon alfa-2a and ribavirin after 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects. Hepatology 52:878A–879A
Lawitz E, Hill JM, Marbury TC, Rodriguez-Torres M, DeMicco M, Quesada J, Shaw P et al (2010) Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451. Hepatology 52:714A–715A
Lawitz E, Rodriguez-Torres M, Denning J, Cornpropst M, Clemons D, McNair L, Berrey M et al (2011) Once daily dual nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidin clinical combination data (the NUCLEAR study). J Hepatol 54:S543
Lawitz E, Gruener D, Hill J, Marbury T, Komjathy S, DeMicco M, Murillo A et al (2011b) Three-day dose ranging study of the HCV NS5A inhibitor GS-5885. J Hepatol 54(1):S481–S482
Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R et al (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366:216–224
Manns MP, Reesink H, Moreno C, Berg T, Benhamou Y, Horsmans Y, Dusheiko G et al (2008) Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. Hepatology 48:1023A
Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D et al (2011) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114–1122
Nettles R, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell NA et al (2008) BMS-790052 is a first-in-class potent hepatitis C virus NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48:1025A
Nettles R, Wang XD, Quadri S, Wu YS, Gao M, Belema M, Lawitz E et al (2010) BMS-824393 is a potent HCV NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic genotype 1 HCV infection. Hepatology 52:1203A–1204A
Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742–1751
Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L et al (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:703–714
Picard O, Cacoub P (2012) Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol 36:437–440
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–1206
Poordad FF, Lawitz EJ, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, Lee SS et al (2012) A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol 56(2):S559
Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H et al (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 108:20509–20513
Reddy R, Rodriguez-Torres M, Gane EJ, Robson R, Lalezari J, Everson GT, DeJesus E et al (2007) Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46:862A–863A
Reesink H, Bergmann J, de Bruijne J, Weegink C, van Lier J, van Vliet A, Keung A et al (2009) Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients. J Hepatol 50(1):S35
Reesink HW, Janssen HLA, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Patel K, Chen A et al (2012) Final results. Randomized, double-blind, placebo-controlled safety, antiviral proof-of-concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment-naive patients with genotype 1 chronic HCV infection. J Hepatol 56(2):S26
Rodriguez-Torres M, Lawitz E, Conway B, Kaita K, Sheikh A, Ghalib R, Adrover R et al (2010) Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients. J Hepatol 52(1):S14
Rouzier R, Larrey D, Gane EJ, Wiercinska-Drapalo A, Chang L, Zhang Y, Gujral B et al (2011) Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a plus ribavirin in previous null-responders. J Hepatol 54(1):S28
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D et al (2007) Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology 132:1767–1777
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW et al (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365:1014–1024
Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, Takahashi S et al (2012) Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin. J Hepatol 56(2):S7
Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A et al (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139:1593–1601
Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, Brain P et al (2011) Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85:6353–6368
Thomas E, Ghany MG, Liang TJ (2012) The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 23:1–12
Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S et al (2011) Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54:50–59
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417–2428
Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C et al (2012) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749–758
Conflicts of Interest
The author has received grant/research support from Gilead and Roche; he has served as an advisor for Abbott, Achillion, Anadys, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Glaxo-SmithKline, Janssen, Merck, Novartis, Pfizer, and Roche.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pawlotsky, JM. (2013). Treatment of Chronic Hepatitis C: Current and Future. In: Bartenschlager, R. (eds) Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Current Topics in Microbiology and Immunology, vol 369. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27340-7_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-27340-7_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27339-1
Online ISBN: 978-3-642-27340-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)